IVF Cube Prag - Publications

Publications

Arce JC, Andersen AN, Fernández-Sánchez M, Visnova H, Bosch E, García-Velasco JA, Barri P, de Sutter P, Klein BM, Fauser BC. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimüllerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection. Fertil Steril. 2014 Dec; 102(6):1633-40.e5. doi: 10.1016/j.fertnstert.2014.08.013. Epub 2014 Sep 23. Online <http://www.sciencedirect.com/science/article/pii/S001502821402072X>.
Visnova H, Huttelova R, Budka S, Bahnikova M. Strategy to prevent the failure of GnRH agonist (GnRH-a) to trigger final oocyte maturation in patients with high risk of OHSS stimulated with antagonist protocol. In Abstracts of the 30^th Annual Meeting of the European Society of Human Reproduction and Embryology. Munich 29 June to 2 July 2014. Poster topic: Reproductive endocrinology. Poster number: P-549. Online <https://www.eshre.eu/~/media/sitecore-files/Annual-meeting/Munich/ESHRE_2014_ABSTRACT-BOOK_opt.pdf>.
Arce JC, Nyboe Andersen A, Fernández-Sánchez M, Visnova H, Bosch E, García-Velasco JA, Barri P. de Sutter P, Klein BM, Fauser CTM. Relation between dose of FE 999049, a recombinant FSH derived from a human cell-line, used for controlled ovarian stimulation and number of oocytes, embryos and blastocysts. In Abstracts of the 30^th Annual Meeting of the European Society of Human Reproduction and Embryology. Munich 29 June to 2 July 2014. Poster topic: Reproductive endocrinology. Poster number: P-492. Online <https://www.eshre.eu/~/media/sitecore-files/Annual-meeting/Munich/ESHRE_2014_ABSTRACT-BOOK_opt.pdf>.
Brezinova J, Visnova H, Huttelova R. Myths about Fertility and ART success rates – Results of the Survey. In Abstracts of the 30^th Annual Meeting of the European Society of Human Reproduction and Embryology. Munich 29 June to 2 July 2014. Poster topic: Psychology and counselling. Poster number: P-338. Online <https://www.eshre.eu/~/media/sitecore-files/Annual-meeting/Munich/ESHRE_2014_ABSTRACT-BOOK_opt.pdf>.
Visnova H, Pierson RA, Mrazek M, García-Velasco, Blockeel, C, Arce JC. Effects of barusiban, a selective oxytocin antagonist, on uterine contractility in the luteal phase after controlled ovarian stimulation. In Sbornik abstract, 22. Sympozium asistovane reprodukce. Brno 13 to 14 November 2012. Online <http://www.meritis.cz/dokumenty/kongresy/43/abstrakt2012.pdf>.
Visnova H, Pierson RA, Mrazek M, García-Velasco, Blockeel, C, Arce JC. Effects of barusiban, a selective oxytocin antagonist, on uterine contractility in the luteal phase after controlled ovarian stimulation. Fertility and Sterility, Sep 1 2012, Volume 98, Issue 3, S183.
Derbyshire E. Nutrition in the Childbearing Years. I. Title. Chichester, UK: Wiley-Blackwell, 2011. 336p. ISBN: 978-1-4443-4477-6.
Crha I, Hruba D, Ventruba P, Fiala J, Totusek J, Visnova H. Ascorbic acid and infertility treatment. Central European Jurnal of Public Health, 2003, Volume 11, Issue 2, 63-7.
Andersen, AN, Fernandez-Sanchez, M, Bosch, E, Visnova, H, Barri, P, Garcia-Velasco, JA, De Sutter, P, Fauser, BJCM, Arce, JC. A randomised, assessor-blind, dose-response trial in patients undergoing COS for IVF/ICSI with a novel recombinant FSH (FE 999049) derived from a human cell line. Human Reproduction, Jun 2013, Volume 28, Issue 3, S351-352.
Visnova H, Pierson RA, Mrazek M, García-Velasco, Blockeel, C, Arce JC. Effects of barusiban, a selective oxytocin antagonist, on uterine contractility in the luteal phase after controlled ovarian stimulation. In Sbornik abstract, 22. Sympozium asistovane reprodukce. Brno 13 to 14 November 2012. Online < http://www.meritis.cz/dokumenty/kongresy/43/abstrakt2012.pdf>.
Visnova H, Pierson RA, Mrazek M, García-Velasco, Blockeel, C, Arce JC. Effects of barusiban, a selective oxytocin antagonist, on uterine contractility in the luteal phase after controlled ovarian stimulation. Fertility and Sterility, Sep 1 2012, Volume 98, Issue 3, S183.
Huttelova R, Kleibl Z, Kleiblova P, Visnova H, Uher P. PCR-PGD pro hereditární nádorové syndromy – first report pro BRCA1/2. Czech and Slovak Conference for Reproductive Gyneacology. Brno, 9. – 10. November, 2010. Published in Prakticka gynekologie, 2010, 13 (suppl. 1): 13-14.
Huttelova R, Visnova H, Uher P. Oocyte vitrification in case of semen deficiency in IVF treatment. Czech and Slovak Conference for Reproductive Gyneacology. Brno, 9. – 10. November, 2010. Published in Prakticka gynekologie, 2010, 13 (suppl. 1): 13-14.
Derbyshire E. Nutrition in the Childbearing Years. I. Title. Chichester, UK: Wiley-Blackwell, 2011. 336p. ISBN: 978-1-4443-4477-6.
Crha I, Hruba D, Ventruba P, Fiala J, Totusek J, Visnova H. Ascorbic acid and infertility treatment. Central European Jurnal of Public Health, 2003, Volume 11, Issue 2, 63-7.
Uher P, Baborova P, Visnova H, Losan P, Martinek P. Our experience with Preimplantation Genetic Diagnosis. Symposium of Assisted Reproduction. Brno, November 21. – 22., 2007. Published in Prakticka gynekologie, 2007; 11 (suppl. 6): p-273.
Chovanec J, Visnova H, Sik S, Petrenko M, Unzeitig V. The influence of the breast cancer chemotherapy to the menstrual cycle. 11th International Meeting of Gynaecological Oncology. May 08-12, 1999, Budapest.
Unzeitig V, Siegelova V, Paseka J, Visnova H. Contraception and STD prevention. In International Congress, Symposium and Seminar Series of the 5th Congress of the European Society of Contraception. 1998, Prague.
Zakova J, Ventruba P, Crha I,Visnova H. Effectiveness of frozen-thawed embryo transfer in the years 1996 and 1997. Human Reproduction, Jun 1998, Volume 13, Special Issue, S297-297.

Clinical trials

Title	A Randomised, Double-blind, Parallel Groups, Placebo-controlled, Multi-centre Study Assessing the Effects of a Selective Oxytocin Antagonist (Barusiban) and a Mixed Oxytocin Antagonist - Vasopressin V1a Antagonist (Atosiban) Administered Intravenously on Luteal Phase Uterine Contractions in Oocyte Donors Supplemented With Vaginal Progesterone
EudraCT No	2007-003158-27
Sponsor	Ferring Pharmaceuticals A/S, Denmark
Sponsor Protocol No	FE 200440 CS09

Title	A Randomized, Open-label, Assessor-blind, Parallel Groups, Multicentre Trial Comparing the Efficacy of MENOPUR Versus Recombinant FSH in Controlled Ovarian Stimulation Following a GnRH Antagonist Protocol and Single Embryo Transfer
EudraCT No	2008-006775-67
Sponsor	Ferring Pharmaceuticals A/S, Denmark
Sponsor Protocol No	FE 999906 CS08

Title	A Randomised, Double-blind, Parallel Groups, Placebo-controlled, Multi-centre Trial in Oocyte Donors Assessing the Effects of Barusiban, a Selective Oxytocin Antagonist, on Uterine Contractions on the Day of Embryo Transfer
EudraCT No	2009-012323-29
Sponsor	Ferring Pharmaceuticals A/S, Denmark
Sponsor Protocol No	FE200440CS11

Title	A randomised, controlled, assessor-blind, parallel groups, multinational, multicentre trial assessing the dose-response relationship of FE 999049 in controlled ovarian stimulation in women undergoing an assisted reproductive technology programme.
EudraCT No	2011-000633-36
Sponsor	Ferring Pharmaceuticals A/S, Denmark
Sponsor Protocol No	000009

Title	A randomised, placebo-controlled, double-blind, parallel groups, multinational, multicentre trial assessing the effect of barusiban administered subcutaneously on the day of transfer on implantation and pregnancy rates in IVF/ICSI patients.
EudraCT No	2012-001622-10
Sponsor	Ferring Pharmaceuticals A/S, Denmark
Sponsor Protocol No	000048

Title	A Randomised, Controlled, Assessor-blind, Parallel Groups, Multicentre, Multinational Trial Comparing the Efficacy and Safety of FE 999049 With Follitropin Alfa (GONAL-F) in Controlled Ovarian Stimulation in Women Undergoing an Assisted Reproductive Technology Programme
EudraCT No	2013-001669-17
Sponsor	Ferring Pharmaceuticals A/S, Denmark
Sponsor Protocol No	000004

Title	A Controlled, Assessor-blind, Parallel Groups, Multicentre, Multinational Trial Evaluating the Immunogenicity of FE 999049 in Repeated Cycles of Controlled Ovarian Stimulation in Women Undergoing an Assisted Reproductive Technology Programme
EudraCT No	2013-001616-30
Sponsor	Ferring Pharmaceuticals A/S, Denmark
Sponsor Protocol No	000071

Title	A phase III, randomized, controlled, single-blind, multicentre, parallel arm trial to assess the efficacy and safety of Pergoveris® (follitropin alfa and lutropin alfa) and GONAL-f® (follitropin alfa) for multifollicular development as part of an assisted reproductive technology treatment cycle in poor ovarian responders, as defined by the European Society of Human Reproduction and Embryology criteria
EudraCT No	2013-003817-16
Sponsor	Merck KGaA
Sponsor Protocol No	EMR200061-005

Title	A Phase 2, Double-blind, Dose-finding, Placebo-controlled Study to Assess the Safety and Efficacy of a Single Oral Administration of OBE001 to Improve Embryo Implantation Following IVF or ICSI
EudraCT No	2014-002254-40
Sponsor	ObsEva SA
Sponsor Protocol No	14-OBE001-013